查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1663452

非处方 (OTC) 止痛药市场，按药品类型、给药途径、配销通路、国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Over-the-Counter (OTC) Pain Medication Market, By Drug Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年非处方 (OTC) 止痛药市场规模价值为 289.426 亿美元，2025 年至 2032 年期间的复合年增长率为 4.20%。

此外，由于生活方式的改变和繁忙的日程安排导致的压力水平升高，人们的头痛、背痛和肌肉痛也随之增加。因此，不服用处方药而自行治疗的趋势日益增长。此外，由于配方创新减少了服药频率并提高了产品有效性，消费者对非处方药的信心也增强了。在未来几年，市场的成长可能会受到替代治疗方案的可用性和对止痛药负面影响的认识不断提高的限制。

非处方 (OTC) 止痛药市场 - 市场动态

全球范围内慢性病发生率不断上升

随着全球慢性病的发生率不断上升，非处方（OTC）止痛药市场急剧增长。需要长期疼痛管理的慢性病（如关节炎、背痛、偏头痛和头痛）的数量一直在稳定增加。据认为，全世界有近 60% 的人患有慢性疼痛问题。随着寿命延长，与年龄相关的身体机能障碍的普遍性也增加了慢性疼痛的可能性。劳动力老化、生活忙碌、工作负担过重以及缺乏体力活动也加剧了这个问题。由于非处方药（OTC）随时可用、价格合理且不需要处方，因此患有慢性疼痛的人经常求助于它们来缓解偶尔或长期的疼痛。据药局称，对布洛芬、对乙酰氨基酚以及外用凝胶和乳膏等知名商品的需求增加。儘管处方止痛药也很常用，但由于对成瘾性、耐受性和副作用的担忧，非处方药正成为更有吸引力的选择。此外，为了防止过量使用鸦片类药物或其他限制性麻醉剂，医生建议将非处方药作为轻度至中度疼痛的初始治疗选择。随着慢性病在全球范围内变得越来越普遍，非处方药（OTC）预计将更频繁地用于疼痛治疗。

非处方 (OTC) 止痛药市场 - 关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年），全球市场预计年复合成长率约为 4.20%

根据药物类型细分，非类固醇抗发炎药物类别预计将在 2024 年占据最大市场份额

根据配销通路细分，医院药房将成为 2024 年的领先细分市场

从地区来看，北美是 2024 年最大的收入来源

非处方（OTC）止痛药市场-細項分析：

全球非处方（OTC）止痛药市场根据药品类型、给药途径、配销通路和地区进行细分。

根据药物类型，市场分为对乙酰氨基酚、非类固​​醇抗发炎药和其他药物。 2024 年，由于世界老龄化人口中疼痛相关疾病病例较多，非类固醇抗发炎药物类别占据主导地位。非类固醇抗发炎药物经常用于缓解老年人经常报告的背痛、关节和肌肉不适以及身体部位肿胀或受损。根据人口趋势，随着预期寿命的增加，未来几十年来已开发国家和发展中国家 65 岁及以上人口的数量将大幅增加。随着年龄的增长，慢性疼痛也变得越来越常见。由于越来越多的老年人依赖非处方药来缓解疼痛，非类固醇抗发炎药物如今已成为许多家庭和药柜中的常见药物。它们的广泛可用性提高了它们在无需处方的情况下治疗与年龄相关的不适方面的普及度以及其已证实的疗效。

根据给药途径，市场分为局部给药、口服给药和非肠道给药。 2024年，市场以口服类为主。这是因为，特别是对于偶尔发生的或间歇性的疼痛，口服药是人们自行服用非处方药最实用、最简单的方法。无需涂抹药膏或凝胶，只需吞服药片或胶囊即可在任何地方治疗疼痛。由于这项重要益处，片剂和液体等口服製剂现已成为自我治疗最受欢迎的选择。对于精力充沛、忙碌的消费者来说，方便用户「随时随地」使用至关重要，因为他们在外出时可能会出现头痛或轻微的肌肉拉伤。顾客可以对口服药物的安全性和有效性更加放心，因为它们比外用药物经过了更彻底的研究和测试。

非处方 (OTC) 止痛药市场 - 地理洞察

2024 年，北美在全球非处方 (OTC) 止痛药市场占据主导地位。该地区完善的医疗保健体系和高度的消费者健康意识推动了非处方（OTC）止痛药的需求。人口老化和慢性疼痛问题也影响持续消费。强而有力的药品法规透过确保产品的品质和安全来增强消费者的信任。製造商的密集行销和广告活动也增加了消费。此外，知名製药企业的存在和零售机构中 OTC 产品的广泛供应巩固了北美在非处方（OTC）止痛药行业的主导地位。

然而，在整个预测期内，预计亚太地区的复合年增长率最快。预计亚太地区非处方（OTC）止痛药市场将显着发展，这主要归功于该地区人口众多、中产阶级不断壮大以及购买力不断增强。随着中国和印度等国家的可支配收入和城市化进程大幅提高，对非处方（OTC）止痛药的需求也随之增加。此外，自我药疗的文化倾向和常见疾病的流行也加速了市场的成长。製药公司正专注于这个市场，并推出一系列非处方（OTC）止痛药来满足不断增长的消费者群体。

非处方（OTC）止痛药市场－竞争格局：

许多跨国製药公司，包括强生、辉瑞、赛诺菲、利洁时集团有限公司、拜耳公司、葛兰素史克公司等，主导非处方（OTC）止痛药市场的竞争环境。品牌标籤和通用标籤也很重要，因为它们提供了经济实惠的替代方案。水杨酸盐、对乙酰氨基酚和非类固醇抗发炎药等镇痛剂的市场定位受行销策略、产品创新和监管因素的影响。全球市场趋势、消费者偏好和分销策略影响非处方（OTC）止痛药的竞争。企业正在尝试采取一些重要措施以获得竞争优势。例如，2023 年 10 月，比利时的 Hyloris Pharmaceuticals 宣布美国 FDA 批准了强效非鸦片类止痛药 Maxigesic IV。 Maxigesic IV 与 AFT Pharmaceuticals 合作开发，旨在用作缓解轻度至中度疼痛和中度至重度疼痛的辅助药物。这种术后输液剂含有 300 毫克布洛芬和 1,000 毫克对乙酰氨基酚，可作为麻醉药物的替代品。

近期发展

2024 年 3 月：美国 FDA 警告某些非处方外用止痛药，不要在雷射除毛、纹身、穿孔和微晶换肤等美容手术之前、期间或之后用于缓解疼痛。六家企业因非法推广这些商品而收到政府的警告信。

2023 年 1 月：天然止痛胶囊是 Medterra 的最新产品。 Medterra 天然止痛药是一种经过专业验证的植物性止痛药，旨在减轻发炎、关节僵硬和肌肉不适，且不会产生非处方 (OTC) 替代品经常出现的不良副作用。

2022年8月：生物製药公司Myovant Sciences和辉瑞宣布，MYFEMBREE（瑞卢戈利克斯、雌二醇和炔诺酮醋酸盐）获得美国FDA批准，作为每日一次的药丸，用于治疗停经前女性中度至重度子宫内膜异位症疼痛。该药物最多可以服用 24 个月。此次批准还涵盖了子宫肌瘤引起的月经过多出血的治疗，并得到了一项开放标籤扩展研究和 3 期试验的证据支持。

目录

第 1 章：非处方 (OTC) 止痛药市场概览

  • 研究范围
  • 市场估计年限

第 2 章：执行摘要

  • 市场片段
    • 非处方 (OTC) 止痛药市场片段（按药物类型）
    • 非处方 (OTC) 止痛药市场片段（依给药途径）
    • 非处方 (OTC) 止痛药市场片段（按配销通路）
    • 非处方 (OTC) 止痛药市场（按国家/地区划分）
    • 非处方 (OTC) 止痛药市场片段（按地区）
  • 竞争洞察

第 3 章：非处方 (OTC) 止痛药主要市场趋势

  • 非处方 (OTC) 止痛药市场驱动因素
    • 市场驱动因素的影响分析
  • 非处方 (OTC) 止痛药市场限制
    • 市场限制的影响分析
  • 非处方 (OTC) 止痛药市场机会
  • 非处方 (OTC) 止痛药市场未来趋势

第 4 章：非处方 (OTC) 止痛药产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景规划
  • 规范架构分析

第 5 章：非处方 (OTC) 止痛药市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • 新冠肺炎疫情后影响分析
    • 表现最佳的市场区隔
    • 边际成长领域
    • 最失败的部分
    • 边际损失部分

第 6 章：非处方 (OTC) 止痛药市场格局

  • 非处方 (OTC) 止痛药市占分析，2024 年
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第 7 章：非处方 (OTC) 止痛药市场 - 依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 乙酰胺酚
    • 非类固醇抗发炎药
    • 其他的

第 8 章：非处方 (OTC) 止痛药市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 主题
    • 口服
    • 肠外

第 9 章：非处方 (OTC) 止痛药市场 - 按配销通路

  • 概述
    • 按配销通路进行细分市场份额分析
    • 医院药房
    • 电子商务
    • 零售药局
    • 居家护理
    • 其他的

第 10 章：非处方 (OTC) 止痛药市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美非处方 (OTC) 止痛药主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按药物类型）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按配销通路划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲非处方 (OTC) 止痛药主要製造商
    • 欧洲市场规模及预测（按国家）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（依配销通路划分）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区非处方 (OTC) 止痛药主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太市场规模及预测（依药品类型）
    • 亚太市场规模及预测（依管理途径）
    • 亚太市场规模及预测（按配销通路划分）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲非处方 (OTC) 止痛药主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依药品类型）
    • 拉丁美洲市场规模及预测（按管理途径）
    • 拉丁美洲市场规模及预测（按配销通路划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲非处方 (OTC) 止痛药主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（依药品类型）
    • 中东和非洲市场规模及预测（按管理路线划分）
    • 中东和非洲市场规模及预测（按配销通路划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其他地区

第 11 章：主要供应商分析-非处方 (OTC) 止痛药产业

  • 竞争仪錶板
  • 公司简介
    • Johnson & Johnson
    • Pfizer Inc.
    • Sanofi SA
    • Reckitt Benckiser Group plc
    • Bayer AG
    • GlaxoSmithKline plc
    • Novartis AG
    • Perrigo Company plc
    • Takeda Pharmaceutical Company Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Ltd.
    • Alkem Laboratories Ltd.
    • Cipla Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4606

REPORT HIGHLIGHT

Over-the-Counter (OTC) Pain Medication Market size was valued at US$ 28,942.6 Million in 2024, expanding at a CAGR of 4.20% from 2025 to 2032.

Over-the-counter (OTC) medications are those that licensed pharmacists dispense without a prescription. Whether at home or work, people frequently turn to over-the-counter (OTC) pain medications to relieve even the smallest physical discomfort. Both generic and brand-name OTC pain relievers come in tablet, pill, cream, ointment, spray, and patch form. The most widely used over-the-counter painkiller, paracetamol, has no anti-inflammatory properties. In the central nervous system (CNS), paracetamol inhibits the production of prostaglandins. The first line of treatment for acute lower back pain has been suggested to be acetaminophen. Over the past few years, the market for over-the-counter painkillers has shown encouraging trends. OTC painkiller demand has been mostly driven by the world's growing population as well as the ageing population that is more susceptible to arthritis and joint pain.

Furthermore, people are experiencing increased headaches, back pain, and muscle aches as a result of elevated stress levels brought on by changing lifestyles and busy schedules. As a result, the tendency to self-medicate without prescription medications has grown. In addition, consumer confidence in over-the-counter medicines has increased due to formulation innovations that decrease dosage frequency and increase product effectiveness. In the upcoming years, the market's growth may be constrained by the availability of substitute treatment options and rising awareness of the negative effects of painkillers.

Over-the-Counter (OTC) Pain Medication Market- Market Dynamics

Increasing frequency of chronic illnesses worldwide

The market for over-the-counter (OTC) pain medications has grown dramatically as a result of the increasing frequency of chronic illnesses worldwide. The number of chronic conditions like arthritis, back pain, migraines, and headaches that need long-term pain management has been steadily increasing. Nearly 60% of people worldwide are thought to experience chronic pain issues. The likelihood of chronic pain is increased by the prevalence of age-related physical impairments brought on by longer lifespans. An ageing workforce, busy lives, an excessive workload, and a lack of physical activity are also exacerbating the issue. Because over-the-counter (OTC) drugs are readily available, reasonably priced, and do not require a prescription, people with chronic pain frequently turn to them for either episodic or long-term relief. The demand for well-known goods that comprise ibuprofen, acetaminophen, and topical gels and creams has increased, according to pharmacies. Even while prescription painkillers are also commonly used, OTC medications are becoming a more appealing option due to worries about addiction, tolerance, and adverse effects. Additionally, in order to prevent the overprescription of opioids or other restricted narcotics, doctors advise OTC pharmaceuticals as the initial therapeutic option for mild to moderate pain. Over-the-counter (OTC) drugs are expected to be used more frequently for pain treatment as chronic illnesses become more prevalent globally.

Over-the-Counter (OTC) Pain Medication Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.20% over the forecast period (2025-2032)

Based on drug type segmentation, the nonsteroidal anti-inflammatory drug category was predicted to show maximum market share in the year 2024

Based on distribution channel segmentation, hospital pharmacies were the leading segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

Over-the-Counter (OTC) Pain Medication Market- Segmentation Analysis:

The Global Over-the-Counter (OTC) Pain Medication Market is segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region.

Based on drug type, the market is divided into Acetaminophen, Nonsteroidal Anti-inflammatory Drug, and Others. In 2024, the nonsteroidal anti-inflammatory drug category held a dominant market share because of the high cases of pain-related disorders in the world's ageing population. NSAIDs are frequently used to alleviate backaches, joint and muscular discomfort, and swollen or damaged body parts that older adults frequently report. According to demographic trends, the number of people 65 and older will rise dramatically over the next several decades in both developed and developing countries as life expectancies rise. As people age, chronic pain also becomes increasingly common. NSAIDs are now commonplace in many homes and medicine cabinets due to the sizable and growing number of senior citizens who rely on over-the-counter drugs for pain management. Their extensive availability boosts their popularity for self-medication of age-related discomforts without a prescription and their demonstrated efficacy.

On the basis of the route of administration, the market is segregated into Topical, Oral, and Parenteral. In 2024, the market was dominated by the oral category. This is because, particularly for sporadic or intermittent pain, oral pills are the most practical and simplest way for people to self-administer over-the-counter pharmaceuticals. Pain treatment without the inconvenience of applying creams or gels is possible anywhere by swallowing tablets or capsules. Oral formulations, such as tablets and liquids, are now the most popular option for self-treatments due to this important benefit. Being user-friendly "on the go" is crucial for energetic, busy consumers who can have headaches or mild strained muscles while out and about. Customers can feel more secure about the safety and efficacy of oral medications because they have undergone more thorough research and testing than topical preparations.

Over-the-Counter (OTC) Pain Medication Market- Geographical Insights

In 2024, North America held a dominant position in the global market for Over-the-Counter (OTC) Pain Medication. The demand for over-the-counter (OTC) pain medications is fueled by the region's established healthcare system and high level of consumer health awareness. The ageing population and the cases of chronic pain problems also influence sustained consumption. Strong pharmaceutical laws promote consumer trust by guaranteeing the quality and safety of products. Manufacturers' intensive marketing and advertising campaigns also increase consumption. Furthermore, North America's dominant position in the over-the-counter (OTC) pain medications industry is reinforced by the existence of well-known pharmaceutical businesses and the extensive availability of OTC goods in retail establishments.

However, throughout the projected period, the Asia-Pacific region is anticipated to see the fastest CAGR. The market for over-the-counter (OTC) pain medications is expected to develop significantly in the Asia-Pacific region mainly because of its large population, growing middle class, and rising purchasing power. The demand for over-the-counter (OTC) pain medications has increased as a result of significant increases in disposable income and urbanization in nations like China and India. Additionally, a cultural propensity for self-medication and the prevalence of common illnesses have accelerated market growth. Pharmaceutical companies are focusing on this market and introducing a range of over-the-counter (OTC) painkillers to cater to the expanding consumer base.

Over-the-Counter (OTC) Pain Medication Market- Competitive Landscape:

Many multinational pharmaceutical companies, including Johnson & Johnson, Pfizer Inc., Sanofi S.A., Reckitt Benckiser Group plc, Bayer AG, GlaxoSmithKline plc, and others, dominate the competitive environment of the over-the-counter (OTC) pain medications market. Branded and generic labels are important as well since they provide affordable substitutes. The market placement of analgesic formulations, such as salicylate, acetaminophen, and NSAIDs, is influenced by marketing strategies, product innovations, and regulatory factors. Global market trends, consumer preferences, and distribution strategies influence Over-the-counter (OTC) pain medications competition. Businesses are attempting to put some important measures into place in order to get a competitive advantage. For instance, in October 2023, Belgium-based Hyloris Pharmaceuticals announced that the USFDA had approved the potent non-opioid pain reliever Maxigesic IV. Developed in partnership with AFT Pharmaceuticals, Maxigesic IV is designed to be used as an adjuvant for mild-to-moderate pain and moderate-to-severe pain. This postoperative infusion, which combines 300 mg of ibuprofen and 1,000 mg of paracetamol, offers an alternative to narcotic drugs.

Recent Development

March 2024: Certain over-the-counter topical analgesics have been cautioned by the U.S. FDA not to be used for pain relief prior to, during, or following cosmetic procedures such as laser hair removal, tattooing, piercing, and microdermabrasion. Six businesses received warning letters from the government for unlawfully promoting these goods.

January 2023: Natural Pain Relief capsules are Medterra's newest offering. A professionally validated plant-based pain reliever, Medterra Natural Pain Relief is designed to reduce inflammation, joint stiffness, and muscular discomfort without the unfavourable side effects that are frequently connected to over-the-counter (OTC) alternatives.

August 2022: The biopharmaceutical business Myovant Sciences and Pfizer announced that MYFEMBREE (relugolix, estradiol, and norethindrone acetate) was approved by the USFDA as a once-daily pill for the treatment of moderate to severe endometriosis pain in premenopausal women. The medication can be taken for up to 24 months. The clearance also covers treatment for excessive menstrual bleeding caused by uterine fibroids, and it is backed by evidence from an open-label extension study and Phase 3 trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Reckitt Benckiser Group plc
  • Bayer AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc
  • Takeda Pharmaceutical Company Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drug
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral
  • Parenteral

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • E-commerce
  • Retail Pharmacies
  • Home Care
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Over-the-Counter (OTC) Pain Medication Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Over-the-Counter (OTC) Pain Medication Market Snippet by Drug Type
    • 2.1.2. Over-the-Counter (OTC) Pain Medication Market Snippet by Route of Administration
    • 2.1.3. Over-the-Counter (OTC) Pain Medication Market Snippet by Distribution Channel
    • 2.1.4. Over-the-Counter (OTC) Pain Medication Market Snippet by Country
    • 2.1.5. Over-the-Counter (OTC) Pain Medication Market Snippet by Region
  • 2.2. Competitive Insights

3. Over-the-Counter (OTC) Pain Medication Key Market Trends

  • 3.1. Over-the-Counter (OTC) Pain Medication Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Over-the-Counter (OTC) Pain Medication Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Over-the-Counter (OTC) Pain Medication Market Opportunities
  • 3.4. Over-the-Counter (OTC) Pain Medication Market Future Trends

4. Over-the-Counter (OTC) Pain Medication Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Over-the-Counter (OTC) Pain Medication Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Over-the-Counter (OTC) Pain Medication Market Landscape

  • 6.1. Over-the-Counter (OTC) Pain Medication Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Over-the-Counter (OTC) Pain Medication Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Acetaminophen
    • 7.1.3. Nonsteroidal Anti-inflammatory Drug
    • 7.1.4. Others

8. Over-the-Counter (OTC) Pain Medication Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Topical
    • 8.1.3. Oral
    • 8.1.4. Parenteral

9. Over-the-Counter (OTC) Pain Medication Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. E-commerce
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Home Care
    • 9.1.6. Others

10. Over-the-Counter (OTC) Pain Medication Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Over-the-Counter (OTC) Pain Medication Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Sanofi S.A.
    • 11.2.4. Reckitt Benckiser Group plc
    • 11.2.5. Bayer AG
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Novartis AG
    • 11.2.8. Perrigo Company plc
    • 11.2.9. Takeda Pharmaceutical Company Limited
    • 11.2.10. Lupin Limited
    • 11.2.11. Sun Pharmaceutical Industries Ltd.
    • 11.2.12. Alkem Laboratories Ltd.
    • 11.2.13. Cipla Ltd.
    • 11.2.14. Dr. Reddy's Laboratories Ltd.
    • 11.2.15. Glenmark Pharmaceuticals Ltd.
    • 11.2.16. Teva Pharmaceutical Industries Ltd.
    • 11.2.17. Boehringer Ingelheim International GmbH
    • 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us